Related Experiment Videos

STAT3 signaling inhibitors for cancer treatment

Rasaq Akinsola1, Jing Xian1, James Turkson1

  • 1Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Cancer Biology Program, Cedars-Sinai Cancer, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.

Trends in Pharmacological Sciences
|August 8, 2026
PubMed

Insights

Targeting Signal Transducer and Activator of Transcription 3 (STAT3) shows promise in cancer treatment. Biomarker-guided strategies and novel STAT3 inhibitors are crucial for improving patient outcomes and accelerating clinical development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Signal Transducer and Activator of Transcription 3 (STAT3) is a key target in cancer therapy.
  • Development of potent, safe, and effective STAT3 inhibitors remains a challenge.
  • Clinical trial data for STAT3 inhibitors show varied responses in advanced cancers.

Purpose of the Study:

  • To review recent advancements in STAT3-targeted cancer therapies.
  • To evaluate preclinical and clinical activities of novel STAT3 inhibitors.
  • To highlight strategies for optimizing STAT3 inhibitor development and application.

Main Methods:

  • Review of recent literature on STAT3 inhibitors.
  • Analysis of preclinical and clinical trial data.
  • Discussion of emerging therapeutic modalities like oligonucleotide technologies and protein degraders.

Main Results:

  • STAT3 inhibition demonstrates antitumor efficacy.
  • Clinical outcomes vary, with phosphotyrosine STAT3 positivity correlating with better responses.
  • New technologies are accelerating the clinical translation of STAT3 inhibitors.

Conclusions:

  • Biomarker-informed approaches are essential for patient selection and optimizing outcomes.
  • Combination therapies may enhance clinical benefits.
  • Artificial intelligence and machine learning can accelerate STAT3 inhibitor development.
Keywords:
STAT3antitumor efficacycancerdrug discoveryinhibitory modalitiestherapy

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...